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Glioblastoma (GBM), the most malignant of the brain tumors is classified on the basis of molecular signature
genes using TCGA data into four subtypes- classical, mesenchymal, proneural and neural. The mesenchymal
phenotype is associated with greater aggressiveness and low survival in contrast to GBMs enriched with proneural
genes. The proinflammatory cytokines secreted in the microenvironment of gliomas play a key role in tumor
progression. The study focused on the role of Oncostatin-M (OSM), an IL-6 family cytokine in inducing
mesenchymal properties in GBM. Analysis of TCGA and REMBRANDT data revealed that expression of OSMR but
not IL-6R or LIFR is upregulated in GBM and has negative correlation with survival. Amongst the GBM subtypes,
OSMR level was in the order of mesenchymal N classical N neural N proneural. TCGA data and RT-PCR analysis in
primary cultures of low and high grade gliomas showed a positive correlation between OSMR and mesenchymal
signature genes-YKL40/CHI3L1, fibronectin and vimentin and a negative correlation with proneural signature
genes-DLL3, Olig2 and BCAN. OSM enhanced transcript and protein level of fibronectin and YKL-40 and reduced
the expression of Olig2 and DLL3 in GBM cells. OSM-regulated mesenchymal phenotype was associated with
enhanced MMP-9 activity, increased cell migration and invasion. Importantly, OSM induced mesenchymal
markers and reduced proneural genes even in primary cultures of grade-III glioma cells. We conclude that OSM-
mediated signaling contributes to aggressive nature associated with mesenchymal features via STAT3 signaling in
glioma cells. The data suggest that OSMR can be explored as potential target for therapeutic intervention.
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Gliomas, the most predominant primary brain tumors in adults and
children are a leading cause of cancer-related deaths. Gliomas are divided
into low grade glioma (LGG) and high grade glioma (HGG) [1,2] and
based on the WHO classification; these tumors are further classified into
4 grades. Grade II and gradeIII are categorized as LGG and are associated
with the slow growth rate and better survival period (3–8 years), however,
have high probability to transform to higher grade. HGG include grade
IV glioblastoma (GBM), the most common and aggressive of brain
tumors in adults and accounts for nearly 75% of all gliomas [3–6].
Invasion and neo-angiogenesis are the hallmarks of GBM and contribute
to reduction of median survival period of b1 year post diagnosis [7].
Although most GBMs share similar histological features such asmicrovascular proliferation and pseudopalisading necrosis, the patients
differ in their response to treatment and survival rates [8–11]. Recently,
GBMs have been reclassified into 4 molecular subtypes—Proneural
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the gene expression profiles using The Cancer Genome Atlas (TCGA)
database [12]. Of the subtypes, mesenchymal phenotype is associated
with greater aggressiveness [13] and low survival in contrast to GBMs
enriched with proneural genes [11]. Moreover, tumors exhibiting PN
phenotype have been found to undergo transition into mesenchymal
phenotype during recurrence [11].
Oncostatin-M (OSM), a pleotropic cytokine belonging to IL-6
family [14], is expressed during inflammation and injury [15].OSM is
associated with multiple biological processes and cellular responses
including growth, differentiation, and inflammation. OSM induces
its biological activity by binding to two distinct heterodimers of
gp130 with either OSM Receptor (OSMR) or leukemia inhibiting
factor receptor (LIFR) [16]. OSM is produced by the macrophages
and microglia in the brain [17] and plays an important role in
regulation of neural precursor cell (NPC) activity [18]. OSM-
mediated signalling is associated with poor prognosis and aggressive-
ness in other solid tumors such as breast and lung cancer [19,20].
Various studies have documented contradictory role of OSM on
glioma progression. Friedrich et al. and Halter et al. showed the
inhibitory role of OSM [21,22] while Krona et al. suggested no effect
of OSM on glioma proliferation [23].
Epithelial-to-mesenchymal transition (EMT) is a phenomenon in
which cells lose epithelial features and acquire MES characteristics
leading to increased invasion and migration [24,25]. Several
transcription factors including SNAI1, SNAI2, TWIST1, ZEB-1
play important role in the MES differentiation [26,27] and aberrant
activation of transcriptional factors such as STAT3, ZEB-1and NFκB
is shown to be responsible for MES shift in the GBM [12,13,28].
STAT3 is activated through phosphorylation of tyrosine 705 in
response to cytokines and growth factors that results in transcription
of diverse genes involved in cell cycle progression, apoptosis, cell
survival, angiogenesis, migration, and invasion [29–31]. More
recently, STAT3 along with C/EBPβ has been reported to function
as synergistic initiators and master regulators of mesenchymal
transformation [13] and persistent activation of STAT3 in GBM
contributes to tumor growth and progression. While the role of IL-6
cytokines is well studied in GBM, little is explored about the
expression of IL-6 cytokine receptor family in progression of glioma
and in subtypes of GBM. In this study, we present in-depth analysis
of expression of IL-6R, OSMR and LIFR in low and high grade
gliomas. We show the significance of OSMR in GBM and
demonstrate its association with mesenchymal subtype. We also
demonstrate that OSM differentially regulates the expression of
mesenchymal and proneural signatures and contributes to aggres-
siveness via STAT3 signaling in gliomas.
Materials and Methods
Cell Lines and Tumor Samples
Human glioma cell lines- LN18 and LN229 were procured from
NCCS cell repository. The cells were grown in DMEMwith 4 mM L-
glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and
supplemented with 5% heat-inactivated fetal calf serum (Gibco
BRL, Carlsbad, CA, USA) and 100 U/ml penicillin and 100 μg/ml
streptomycin (Sigma-Aldrich, St Louis, MO) in 5% CO2 humidified
incubator at 37°C. The cells were treated with 50 ng/ml of OSM in
media containing 5% heat-inactivated fetal calf serum (Gibco BRL,
Carlsbad, CA, USA) unless otherwise mentioned.Glioma tumor cells-Informed consent was obtained from patients
for tissue procurement in accordance with the protocol approved by
the institutional ethics committee of NCCS. The tumor samples were
collected during tumor removal surgery performed at Sasoon hospital,
DY Patil Medical College, Hospital & Research Centre and Inamdar
hospital, Pune. The glioma tumors were classified into different
grades (WHO criteria) by pathologist. The tumor tissue samples were
finely chopped followed by enzymatic dissociation and were then
incubated in DMEM supplemented with antibiotics. Cultures were
established by passaging in DMEMmedium with 10% FBS. Cultures
between 10 to 20 passages were used in the study. Normal brain tissue
RNA was procured from Ambion (Invitrogen).
Immunofluorescence Staining
Cells were grown on cover slips for 24 hours, followed by either
transfection for 72 hours or treatment with cytokines. Cells were fixed
with 3.7% paraformaldehyde for 10 min and permeabilized for 5 min
with 0.2% triton X-100. After blocking for 1 hour with 3% BSA, cells
were incubated with primary antibodies for 2 hours followed by
appropriate Cy3 labeled secondary antibodies (Molecular Probes,
Invitrogen) for 60 min at room temperature. DAPI was used for
nuclear staining. Images were acquired using confocal laser scanning
microscope (Carl Zeiss or Leica, Germany).
MTT Assay
Cellular viability was assessed in control and OSM treated cells by
MTT assay. Cells grown for 24 hours were trypsinized and plated at
density 10 × 103 per 100 μl medium per well in flat bottomed 96 well
tissue culture plates. After 24 hours, they were treated with various
concentrations ofOSMand incubated for different time points. 10μl of
5 mg/ml of MTT was added to wells and further incubated for 4 hours
at 37°C. The crystals formed were dissolved in 10% SDS- 0.01 N HCl
and absorbance was measured at 640 to 570 nm. The percent viable cell
number was calculated by assuming the absorbance obtained for control
at each time point as 100%.
Proliferation Assay
Cellular proliferation was assessed in control and OSM treated cells by
[3H]-thymidine incorporation assay. Cells grown for 24 hours were
trypsinized and plated at density 10 × 103 per 100 μl per well in flat
bottomed 96 well tissue culture plates. After 24 hours incubation, various
concentrations of OSM were added and incubated for 48 hours. The
effect on cell proliferation was measured by adding 0.5uCi [3H]-
thymidine, 18 hours prior to termination of the assay. Cells were
trypsinzed and transferred to fresh plate and harvested on strips of fiber
glass filter paper with use of Nunc harvester and radio activity associated
with individual samples wasmeasured using a liquid scintillation counter.
The percent incorporation was calculated by considering incorporation
into control (untreated) cells as 100%.
Neurosphere Assay
The GBM primary culture (G1) cells were cultured with or without
transfections using siRNA Control or siRNA for STAT3 in serum-free
DMEMmedium. After 60 hours of incubation, cells were trypsinized and
1000 cells were seeded into the low attachment 6 well plate in serum-free
media containing DMEM/F12 with 1X B27supplement (GIBCO), 20
ng/ml of bFGF andEGF (Peprotech).Cultureswere incubated for 10 days
and OSM (50 ng/ml) was added every 2 days throughout the assay.
Number and size of spheres formedweremeasured using Image J software.
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Cells were harvested and lysed using RIPA lysis buffer (120 mM
NaCl, 1% Triton X-100, 20 mM Tris–HCl, pH 7.5, 100% glycerol,
2 mM EDTA and protease inhibitor cocktail, Roche, Germany).
Total protein (35 μg) was electrophoresed on 10% SDS polyacryl-
amide gels and electroblotted onto PVDF membrane (Millipore,
Bedford, MA,). After blocking with 5% BSA at room temperature,
the blots were probed with primary antibodies such as pSTAT3 (Y-
705), total STAT3 (Cell signalling technology, Danvers, MA),
YKL40, Olig2 (Santacruz biotechnology), Fibronectin (Sigma-
Aldrich, St Louis, MO) overnight at 4°C. The bands were visualized
by chemiluminescence using Super Signal West Femto Maximum
Sensitivity Substrate (Pierce, USA). Actin was used as loading control.
Real-Time PCR
RNA isolation was performed using TRIzol reagent (Invitrogen,
Carlsbad, CA) and reverse-transcribed into cDNA (Promega) according
to the manufacturer’s instructions. Quantitative real time PCR was
performed using SYBR Green Supermix (Biorad) in Realplex Real-Time
Thermal Cycler (Eppendorf). The profile of thermal cycling consisted of
initial denaturation at 95°C for 2 min, and 40 cycles at 95°C for 15 s and
60°C for 45 s for primer annealing and extension. Melting curve analysis
was used to determine the specific PCR products. All primers used for
Real-Time PCR analysis were synthesized by Integrated DNA
Technologies, India. GAPDH was used as an internal control. The
changes in the threshold cycle (CT) values were calculated by the
equation ΔCT = CT (target) − CT (endogenous control) and fold difference was
calculated as 2−Δ (ΔCT
) .
Sequence of Primers
YKL 40-L–primer: 5-′AATTCGGCCTTCATTTCCTT -3′,
R-primer: 5’-GATAGCCTCCAACACCCAGA-3’.
Fibronectin-1–L-primer:
5′-CTCTTCATGACGCTTGTGGA-3′,
R-primer: 5′-ATGATGAGGTGCACGTGTGT-3′,
Olig2-L-primer: 5′-TAGAACTGTGGCCGTTCCTC-3′,
R-primer: 5′-TCGGCAGTTTTGGGTTATTC-3′,
DLL3-L-primer: 5′-GGAATCGCCCTGAAGATGTA-3′,
R-primer: 5′-ATCGAGGAAGGGTAGGGAA-3′,
GAPDH-L-primer: 5′-ATGGGTGGAATCATATTGGAA-3′,
R-primer: 5′-GAAGGTCGGAGTCAACGGATT-3′.
Transfections
Cells grown to 70% confluency were transfected with ON-TARGET
plus SMART pool, human STAT3 siRNA or nontargeting siRNA
(Dharmacon, Inc.) using Lipofectamine 2000 (Invitrogen). After 72 hours,
the cells were treated with OSM (50 ng/ml). Efficiency of transfection was
assessed by immunofluorescence staining or western blotting.
Gelatin Zymography
Cells were cultured in 24 well plates. After 24 hours the medium was
washed and replaced with serum-free medium and treated with OSM.
The conditioned medium was collected after 12 hours. Equal volume of
conditioned medium was mixed with 5× Laemelli’s sample buffer and
electrophoresis was performed at 65volts (constant voltage). The gels were
washed twice with washing buffer (50 mM Tris-Cl, pH 7.5 and 2.5%
Triton X-100) for 30 min and incubated overnight at 37°C in
renaturation buffer (50 mM Tris-Cl, pH 7.6, 10 mM CaCl2, 150
mMNaCl, and 0.05%NaN3). Gels were stained with 0.2% CoomassieBrilliant Blue R-250 in 40% isopropanol and destained using 7% glacial
acetic acid. The activity of MMP-2 and MMP-9 was recorded by
acquiring gel images.
Scratch Wound Healing Assay
Glioma cells were seeded in 6 well plates and grown to 80%
confluency. The cells were pre-treated with actinomycin D (100 ng/ml)
for 3 hours and scratch was made with a pipette tip. Cells were treated
with OSM (50 ng/ml) in the serum free medium. Randomly chosen
fields (n = 5) were used for imaging at 0 and 16 hours time points. The
width of each scratch was measured by Photoshop (Adobe) software,
normalized and represented as the fold change of width measured at time
0 hours.
Invasion Assay
Cells were seeded in a 60 mm petridish and cultured for 24 hours
followed by transfection with siRNA for 72 hours. Cells were
dislodged using TPVG and conditioned media was collected and
stored at 4°C. Cells (4 × 105) in 0.5 ml of serum free DMEM were
incubated with OSM (50 ng/ml) for 30 min. Matrigel invasion
chamber was rehydrated with serum free medium for 2 hours at 37°C.
The cell suspension was added to the inner chamber and conditioned
media to the outer chamber. After incubation for 22 hours, the cells
in the inserts were fixed with 4% PFA, stained with 0.2% crystal
violet and photographed. Also, dye was eluted and the color intensity
was measured at 540 nm on a spectrophotometer (molecular devices).
TCGA and REMBRANDT Data Analysis
TCGA data base (https://tcga-data.nci.nih.gov/tcga) was used to
acquire level 3 data of Agilent platform for 97 Glioblastoma (GBM), 27
Lower Grade Glioma (LGG) and 10 normal cases. Gene expressions of
OSMR, LIFR and IL-6R in normal, LGG andGBMwere analyzed. The
mean and SD values were calculated and analyzed for significance
between groups and subtypes.Molecular sub-class was predicted from the
subtype metagene score as defined by the Verhaak et al. [12]. Pearson
correlation coefficient between the expression of OSMR and subtype
molecular signature genes was performed. Comparisons of survival period
with the expression of receptor subunits in all gliomas (n = 343) and
GBM (n = 181) was performed with data from the REpository of
Molecular BRAin Neoplasia DaTa (REMBRANDT)- a portal for brain
tumors. Kaplan-Meier plot for highest intensity probe (204004_at) for
samples were plotted and analysis was done using the log-rank test.
TCGAdatawas also used for survival analysis and chi-square test was used
to calculate p-values. Survival was compared between up-regulated and
intermediate expression of OSMR expression in both REMBRANDT
and TCGA data.
Statistical Analysis
The data were represented asmean ± SD and analyzed for independent
student’s t test. Kaplan-Meier estimates (log-rank test) and chi-square test
were used to study if a variable was associated to the survival of glioma
patients. Pearson’s correlation test was used for correlation studies andPb
.05 was assigned significance.Results
OSMR is Up-Regulated in GBM and is AssociatedWith Poor Survival
The TCGA database includes glioma cases analyzed on Affymatrix
and Agilent platforms. Since the study focused on both LGG and
Figure 1. Expression profiles of IL-6 family receptor genes and their correlation with glioma patient survival. (A),(B)and(C) Box whisker
plots for Log2 expression intensities of OSMR, LIFR and IL-6R respectively in normal (n = 10), LGG (n = 27) and in GBM (n = 97) from
Agilent platform of the TCGA database. *p b 0.0001, GBM vs. Normal brain tissue samples. #p b 0.0001, LGG vs. GBM. (D) Kaplan-Meier
graph showing probability of survival of All glioma patients in relation to OSMR expression level, analysed from REMBRANDT database.
The number of patients with up-regulated OSMR expression in the group is 142, whereas the number of patients with intermediate levels
of OSMR is 96, and 5 patients showed down-regulation of OSMR expression. The p-rank value test analysis showed that the P value
between the intermediate and up-regulated levels is less than .0001. (E) Kaplan-Meier graph showing probability of survival of GBM
patients in relation to OSMR expression level, analyzed from TCGA database. The number of patients with up-regulated OSMR expression
in the group is 81, whereas the number of patients with intermediate levels of OSMR is 12. The P value between the intermediate and up-
regulated levels is less than .04.
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of samples was included for analysis. The expression of IL-6 cytokine
family receptors was analyzed in human LGG (n = 27), HGG (n =
97) and in normal (n = 10) samples (Table W1A). The analysis
revealed that expression of OSMR is significantly higher (2.7 fold) in
GBM compared to LGG and normal samples (Figure 1A), while
LIFR is upregulated in LGG but not in GBM compared to controls
(Figure 1B). No significant difference in the IL-6R expression is
observed between the groups (Figure 1C).
The data from the REMBRANDT database was used for the Kaplan-
Meier analysis. The analysis was performed for the expression of receptors
with the probability of survival in all glioma (n = 343) and in GBM (n =
181). Samples with high expression (tumor samples with expression value
b = (mean (normal samples)- SD (normal samples) of OSMR
(Figure 1D), LIFR and IL-6R (Figure W2, A and C) correlated with
low survival period in all gliomas with log-rankP values of b .0001, .0273
and b .0001, respectively (Figure W1B). Interestingly, in GBM, theOSMR (Figure W1A) and not IL-6R or LIFR expression is associated
with poor survival with log-rank P values of 0.049, 0.233, and 0.634,
respectively (Figure W2, B and D) (Table W1 B and C). Kaplan-Meier
analysis of all GBM patients revealed that patients with high OSMR
expression correlated with poor survival compared to cases with
intermediate expression (Figure 1D).
TCGA data was also used for association between survival and
expression of receptors in LGG and HGG (GBM) by performing
Kaplan-Meier analysis. In GBM samples the expression of OSMR
was significantly correlated with the poor survival (P = 0.04)
(Figure 1E) whereas there was no correlation observed in LGG
(Figure W3A). LIFR expression was associated with poor survival in
LGG (P = 0.048) but not in GBM (Figure W4, A and B). IL6R
expression showed no correlation with the poor survival in LGG as
well as in GBM (Figure W4, C and D). Figure W3, B and C, show
the P values calculated using chi-square test. The REMBRANDT
database has only five “all glioma” and two GBM cases; furthermore,
Figure 2. Differential expression pattern of OSMR gene in GBMmolecular subtypes. (A) Box whisker’s plot for Log2 expression values of
OSMR in different GBM sub-types and in normal brain tissue samples from Agilent platform of TCGA database. *P b .05, Mesenchymal
vs. classical; ***P b .0005, Mesenchymal vs. neural or proneural. (B) Pearson’s correlation analysis between the expression of Proneural
signature genes DLL3 (r=−0.60592, p = 4.831e-11), Olig2 (r=−0.47713, p = 7.77e-07) and BCAN (r=−0.51152, p = 8.584e-08) with
OSMR expression. (C) Pearson’s correlation analysis between the expression of Mesenchymal signature genes fibronectin (r= 0.458792,
p = 2.288e-06), YKL40 (r = 0.550732, p = 5.079e-09) and vimentin (r = 0.589645, p = 2.09e-10) with OSMR expression.
Figure 3. Expression of OSMR, Olig2 and YKL40 in different grades of glioma. Expression of (A) OSMR, (B) Olig2 and (C) YKL40 at m-RNA
transcript level among different grades of gliomas assessed by quantitative real-time PCR. The expression level was normalized to normal
brain tissue mRNA. GAPDH was used as internal control.
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Figure 4. Effect of OSM on the expression of Mesenchymal and Proneural signature genes in GBM. (A) and (B) Expression of
Mesenchymal and Proneural markers at transcript level in LN18 and LN229 respectively, measured by quantitative real-time PCR. Data is
represented as mean +/− SD of two experiments done in duplicates. *P b .05, untreated vs. OSM (50 ng/ml) treated. (C) Protein level
variation of Mesenchymal and Proneural markers in LN18 and LN229 treated with OSM (50 ng/ml) detected by western blot analysis.
(D) Expression of YKL40 and fibronectin (Mesenchymal markers) in LN18 and LN229 treated with OSM (50 ng/ml) visualized by
immunofluorescence staining. Magnification 60×, Bars 20 μm.
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survival. There was no statistical significance between low OSMR
expression and survival in this group. The survival analysis from both
REMBRANDT and TCGA data suggests high OSMR level as a
prognostic risk factor in GBM.
OSMR Expression is Associated with Mesenchymal Subtype
Recently, based on The Cancer Genome Atlas (TCGA) data
GBM has been classified into four genetic subtypes -mesenchymal,
classical, neural and proneural characterized by aberrations in genes
including PDGFRA/IDH1, EGFR, and NF1 [12]. Molecular sub-
class was predicted from the subtype metagene score as defined by the
Verhaak et al. [12]. Analysis of data in subtypes of GBM revealed that
OSMR was significantly higher in all the GBM subtypes compared to
control but is highest in mesenchymal group (n = 31) (3.7 fold
change), followed by classical (n = 24) (2.9-fold change) and neural (n
= 8) (2.5-fold change) and lowest in proneural subtype (n = 34) (1.8-
fold change) (Figure 2A and Table W2). Between the subgroups,
OSMR level was significantly different between mesenchymal vs.
neural groups (p = 0.02) and mesenchymal vs. proneural groups (p =0.0001) (Table W2). Further analysis was performed to examine the
association of OSMR with signatures genes of GBM subtypes using
Pearson’s correlation analysis. As depicted in Figure 2B, OSMR
showed significant positive correlation with mesenchymal signature
genes, YKL40/CHI3L1 (r = 0.55), fibronectin(r = 0.458), vimentin
(r = 0.59) and negative correlation with proneural signature genes
DLL3 (r = −0.61), Olig2 (r = −0.48) and BCAN (r = −0.51)
(Figure 2C).None of the classical and neural signature genes
correlated with the expression of OSMR (Table W3). Additionally,
STAT3 target genes also showed significant positive correlation with
the expression of OSMR. These genes are CCL2 (r = 0.56), TGFB1
(r = 0.43), IL6 (r = 0.35), CD80 (r = 0.37), NOS2 (r = 37) and
VEGFA (r = 0.35) (Table W4).
The correlation data from TCGA analysis was validated in primary
cultures of glioma tumor samples of different grades. Transcript levels
of OSMR and CHI3L1/YKL-40 (mesenchymal) and Olig2 repre-
senting proneural type was assessed by Real-time PCR. As depicted in
Figure 3A, five out of six GBM samples showed elevated OSMR level
compared to grade II and grade III glioma tumors. Also, the samples
with high OSMR display high CHI3L1 expression and low Olig2
Figure 5. Effect of OSM on the expression of Mesenchymal and Proneural signature genes in primary GBM culture. (A) Expression at
transcript level of Mesenchymal and Proneural markers in primary culture G1measured by quantitative real-time PCR. Data is represented
as mean +/− SD of two experiments done in duplicates. *P b .05 untreated vs. OSM treated. (B) Protein level variation of Mesenchymal
and Proneural markers in primary culture G1 treated with OSM (50 ng/ml) detected by western blot analysis. The blots are representative
of three independent experiments. (C) Expression of YKL40 and fibronectin (Mesenchymal markers) in primary culture G1 treated with
OSM (50 ng/ml) visualized by immunofluorescence staining. The images are representative of three independent experiments.
Magnification 60×, Bars 20 μm.
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correlation between the OSMR and a proneural marker Olig2
(Figure 3, B and C).
OSM Induces Mesenchymal Markers and Decreases
Proneural Signature Genes in GBM
Based on our data that OSMR is markedly expressed and is
associated with mesenchymal phenotype in GBM, it was of interest to
examine the influence of OSM on the expression of mesenchymal and
proneural signature genes. For this purpose, human GBM cell lines
LN18 and LN229 showing basal levels of OSMR (Figure W6B) were
treated with OSM (50 ng/ml) for 12 hours and tested for a panel of
markers. As shown in Figure 4, A and B, the transcripts of
mesenchymal markers-fibronectin and YKL-40 were increased
significantly, while Olig2 and DLL3- genes related to proneural type
were reduced markedly in both the cell lines. The effect of OSM was
further confirmed at protein level by western blotting analysis (Figure 4C)
and immunofluorescence staining (Figure 4D) after treating cells with
OSM (50 ng/ml) for 48 hours. Similar results were observed in primary
cultures derived from GBM tumor G1 (Figure 5). These data suggestedthat OSM regulates the mesenchymal and proneural signature genes in
glioma cell lines as well as in primary culture.
OSM Induces Invasion and Migration in Glioma
Migration and invasion are hallmarks of mesenchymal transfor-
mation and contribute to aggressive nature of GBM [13]. A recent
report by Bhat et al. showed that wound healing genes are top
upregulated genes cluster in GBM mesenchymal subtype samples but
not in the proneural samples [28]. We evaluated the invasive potential
of glioma in response to stimulation with OSM. Our data by matrigel
invasion assay revealed that OSM enhanced the invasiveness
significantly compared to untreated cells in cell lines and primary
cultures (Figure 6, A and B). In GBM, increased activity of matrix
metalloproteinases (MMPs), MMP-2 and MMP-9 play a key role in
invasion [32]. OSM enhanced MMP-9 activity by N2 fold as
measured by gelatine zymography in the GBM cells, the effect was
significantly greater in LN18 and primary culture- G1 compared to
LN229 (Figure 6, C and D). On these lines, our data by wound
healing assay revealed that OSM significantly increased cell migration
as compared to controls in LN18 and LN229 cells (Figure 6, E
Figure 6. OSM enhances the invasion and migration in GBM. (A) Invasive potential of LN18, LN229 and G1 assessed using matrigel
invasion assay. Graphical representation of the fold change estimated from absorbance values at 540 nm. Data is represented asmean+/−
SDof twoexperiments done in duplicates. *p b 0.05, untreated vs. OSM (50 ng/ml) treated. (B)MMP-9 andMMP-2 levels of LN18, LN229 and
G1 estimated using conditioned medium subjected to gelatin zymography analysis. The zymogram is representative of three independent
experiments. Graphical representation of the mean densitometric values of MMP-9 band. Data is represented as mean +/− SD of three
experiments. *P b .05 untreated vs. OSM (50 ng/ml) treated. (C) Migration capacity of LN18 and LN229. The images are representative of
three independent experiments. Data is represented as mean +/− SD of two experiments done in duplicates. *P b .05 untreated vs.
OSM (50 ng/ml) treated.
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assessed by MTT assay and [3H]-Tritiated thymidine incorporation
assay respectively. Viability and proliferation was not affected by
OSM treatment (Figure W5).
OSM-Induced Mesenchymal Phenotype is STAT3 Dependent
OSM is a classical activator of STAT3, a transcription factor that
mediates many important functions of cytokines and growth factors [33].
OSM induced the activation of STAT3 with its translocation into the
nucleus in LN18, LN229 and G1 cells (Figure W6A). Further
experiments were directed to investigate the role of STAT3 in OSM-
induced mesenchymal phenotype. We observed that silencing of STAT3
abrogated the expression of mesenchymal signature genes- fibronectin and
YKL-40 induced by OSM in LN18 and LN229 (Figure 7, A and B). To
confirm the result at protein level western blotting was performed. The
result revealed that OSM regulated the expression of mesenchymal
markers andproneural signature genes throughSTAT3signaling (Figure 7,
C and D). The immunofluorescence staining (Figure 8, A and B) also
supported the role of STAT3 in OSM- induced differential regulation of
mesenchymal and proneural signature genes.
TheOSM induced invasion in LN18 andG1was decreased 2 and 3
fold respectively, in STAT3 knockdown cells compared to untransfected
OSM treated cells (Figure 9,A andB).MMP-9 activity also abrogated with
the knockdown of STAT3 compared to the OSM induced untransfected
cells (2.5 and 1.5 fold in LN18 and G1 cells respectively) (Figure 9, C
andD). FigureW7, shows similar results in LN229.These results suggested
the role of STAT3 in OSM induced mesenchymal phenotype in glioma.The cells expressing increased mesenchymal properties have an
increased ability to exhibit self-renewal capacity [34]. The neurosphere
assay performed in primary GBM culture, revealed that the treatment of
OSM induced significant increase in the number of neurospheres but
there was no variation in size of neurospheres. Silencing of STAT3 using
siRNA inhibited the neurosphere formation induced by OSM
(Figure 9, E and F). This signifies the role of STAT3 in the OSM
induced self-renewal capacity in glioma.
OSMInduces theMesenchymal Phenotype in LowerGradeGlioma.
LN18, LN229 and G1 cells displayed detectable levels of
mesenchymal signature markers and OSM enhanced the expression
of these markers. It was of interest to address whether OSM could
induce mesenchymal markers in lower grades of gliomas. For this
purpose, we used primary culture of a grade III -glioma cells
(designated as G19). As shown in Figure 10A, OSM induced
significant expression of mesenchymal signature genes and reduced
level of proneural genes. Immunofluorescence staining revealed that
YKL-40 and fibronectin are below the level of detection in G19 cells
and were induced on treatment of OSM for 48 hours (Figure 10B).
Discussion
Although the role of IL-6 family of cytokines in progression of
gliomas is well studied [14], little is known about the expression of IL-
6 receptors in gliomas and more importantly in the subtypes of
GBM. We sought to evaluate the role of three members of IL-6
cytokine family receptors-IL-6R, LIFR and OSMR in gliomas.
Figure 7. Role of STAT3 in OSM induced Mesenchymal signature markers. LN18 cells were treated with STAT3 si RNA (100nM) followed
by OSM (50 ng/ml). (A) and (B) Expression at transcript level of Mesenchymal markers in LN18 and LN229 respectively, measured by
quantitative real-time PCR. Data is represented as mean +/− SD of two experiments done in duplicates. *P b .05, Untransfected + OSM
vs. siRNA STAT3 transfected + OSM. (C) and (D) Protein level variation of Mesenchymal and Proneural markers in LN18 and LN229
respectively, detected by western blot analysis. The blots are representative of three independent experiments.
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remarkably higher in GBM compared to LGG, while LIFR is
upregulated in LGG but not in GBM. The observation that IL-6R
expression was not significantly different between the groups was
surprising as IL-6 mediated signaling is documented to be important
in tumor progression [2,14]. While high expression of these receptors
correlated with low survival period in gliomas, in GBM only OSMR
expression correlated with poor survival. In LGG the expression of
OSMR and IL6R showed no correlation while LIFR showed
association with the poor survival. Our results with Kaplan-Meier
analysis of GBM patients from REMBRANDT and TCGA data
revealed that samples with high expression of OSMR showed poor
survival compared to cases with intermediate expression. This data
strongly suggest high OSMR level as a prognostic risk factor in GBM
and amongst the members of IL-6R family, OSMR might be of
greater significance in progression of glioma.
A new dimension was unraveled in field of glioma research with
classification of glioblastoma into distinct subtypes. Verhaak et al.
classified GBM into four subtypes- mesenchymal, classical, neural
and proneural based on the expression of molecular signature genesusing TCGA data [12]. The mesenchymal phenotype is associated
with highly invasive feature and angiogenesis. Recent studies with
gene expression profiles have established that overexpression of a
“mesenchymal” signature genes and loss of a proneural signature
genes are significantly associated with the poor prognosis group of
glioma patients [11]. Another study showed the link between EMT
process and mesenchymal subtype but not in other subtypes of GBM,
and also provided evidence for a negative correlation between the
genetic signature of EMT and neural stem marker CD133 [35]. Our
analysis of the TCGA data, that OSMR expression was highest in the
mesenchymal subtype and lowest in the proneural subtype prompted
us to examine the correlation of OSMR with expression of
mesenchymal and proneural signature genes. Interestingly, we
found a strong positive correlation of OSMR expression with
mesenchymal signature genes, YKL40/CHI3L1, fibronectin and
vimentin. YKL-40, a member of mammalian chitinase-like proteins
has been shown to be associated with poor prognosis in many cancers
including glioma [36]. In contrast, OSMR expression has a negative
correlation with proneural signature genes DLL3, Olig2, and BCAN.
The association of these sets of genes with OSMR was strengthened
Figure 8. Role of STAT3 in OSM induced Mesenchymal signature markers. LN18 cells were treated with STAT3 si RNA (100nM) followed
by OSM (50 ng/ml). (A) and (B) Expression of YKL40 and Fibronectin (Mesenchymal markers) in LN18 and LN229 respectively visualized by
immunofluorescence staining. The images are representative of three independent experiments. Magnification 60×, Bars 20 μm.
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glioma tumors. Additionally, the data from TCGA analysis showed
no correlation between expression of OSMR with the classical or
neural signature genes.
A recent study by Carro et al. demonstrated the combined role of
C/EBPβ and STAT3 as master regulators that activate expression of
mesenchymal genes in malignant glioma [13]. Multiple pathways
including JAK/STAT are activated during GBM progression [33].
The JAK/STAT-mediated signaling pathway is activated in response to
interleukin (IL-6) family cytokines through activation of transcription
factor STAT3, that regulates expression of genes involved in diverse
functions such apoptotic, proliferation, differentiation. Elevated level of
activated STAT3 in glioblastoma contributes to tumor progression
[37,38]. Increased OSM expression has been reported in a variety of
cancers, includingmalignant glioma [39] andOSMsignaling is associated
with poor prognosis and aggressiveness in other solid tumors such as
breast and lung cancer [40,41]. The correlation analysis revealed that the
expression of OSMR and the STAT3 target genes CCL2, TGFB1, IL6,
CD80,NOS2 andVEGFAwas positively correlated, thereby implicating
STAT3 as a mediator of OSM induced functions.
Since our data revealed high expression of OSMR in mesenchymal
type of GBM and OSMR has a negative correlation with proneural
markers, it was of interest to examine whether OSM regulates
mesenchymal and proneural markers in GBM cells. In this regard, we
found that in GBM cell lines and primary cultures, OSM enhanced
the transcript and protein levels of mesenchymal markers-fibronectin
and YKl-40. Consistent with the expression of mesenchymal features,
we found that OSM-induced aggressive characters were associated
with enhanced MMP-9 activity, increased cell migration and
invasion. Physiologically, OSM is reported to decrease the pool ofneural progenitor cells in subventricular zone and hippocampus
regions and mice lacking OSMR show accumulation of these cells,
indicating the role of OSM -mediated signaling in NPC homeostasis
[18]. It is noteworthy that in our study, OSM reduced the expression
of proneural related genes -Olig2 and DLL3 in GBM cell lines and
primary cultures. Furthermore, silencing of STAT3 abrogated the
effect of OSM suggesting the role of STAT3 signaling in regulating the
expression of mesenchymal markers. To assess the impact of this data, we
addressed whether OSM is able to induce mesenchymal phenotype in
low grade glioma.We found that OSM induced YKL-40 and fibronectin
and reduced proneural genes-Olig2 and DLL3 in primary culture of
gliomas. Halliday et al. reported a shift in proneural to mesenchymal
phenotype inGBM after radiation exposure which was related to increase
in pSTAT3 [42]. The aquisition of mesenchymal traits is associated with
increased self -renewal capacity [34]. The neurosphere assay indicated the
role of STAT3 in the OSM induced self-renewal capacity in GBM
primary culture.
Taken together, the findings provide evidence for a positive
correlation of OSMR with mesenchymal GBM and a negative
association with proneural signature genes. The data also points to
OSMR as a prognostic risk factor in GBM. We further demonstrated
that OSM-OSMR mediated signaling via STAT3 has an important
role in driving the glioma cells towards mesenchymal type. This data
is significant as the mesenchymal subtypes are demonstrated to have
poor prognosis compared to proneural tumors [43]. The findings
underscore the role of OSMR in GBM and suggest that OSMR can
be explored as potential target for therapeutic intervention and
inhibitors to OSMR may be active against malignant gliomas.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.01.001.
Figure 9. Role of STAT3 in OSM induced invasion potential and self- renewal. LN18 and G1 cells were transfected with STAT3 si RNA
(100nM) followed by treatment of OSM (50 ng/ml).(A) Invasive potential assessed using matrigel invasion assay. (B) Graphical
representation of the fold change estimated from absorbance values at 540 nm is represented as mean +/− SD of two experiments done
in duplicates. *P b .05, Untransfected + OSM vs. siRNA STAT3 transfected + OSM. (C) MMP-9 and MMP-2 levels estimated using
conditioned medium subjected to gelatin zymography analysis. The zymogram is representative of three independent experiments.
(D) Graphical representation of the average densitometric values of MMP-9 band. *P b .05 Untransfected + OSM vs. siRNA STAT3
transfected + OSM. (E) G1 cells were transfected with control or STAT3 si RNA (100 nM) and seeded in low attachment plate for
neurosphere assay followed by OSM (50 ng/ml) treatment. Magnification 20×. Scale: 50 μm. (F) Graphical representation of number of
Neurospheres formed is represented as mean +/− SD of two experiments done in duplicates. *P b .05, Untreated vs. OSM. #P b .05,
Untransfected + OSM vs. siRNA STAT3 transfected + OSM.
Figure 10. Effect of OSM in lower grade glioma. (A) Expression at transcript level of Mesenchymal and Pro-Neural markers in primary
culture G19measured by quantitative real-time PCR. Data is represented asmean+/− SD of two experiments done in duplicates. *P b .05
untreated vs. OSM treated. (B) Expression of YKL40 and Fibronectin (Mesenchymal markers) in primary culture G19 treated with OSM
(50 ng/ml) visualized by immunofluorescence staining. The images are representative of three independent experiments. Magnification
60×, Bars 20 μm.
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